Immix Biopharma (IMMX) Stock Forecast: StockMap's 2-Week Call
IMMX stock forecast: StockMap's model leans Underperform on Immix Biopharma for the two weeks after the Nov 19 close, toward IMMX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.
Immix Biopharma last closed at $7.04, -0.98% on the session.
Against the IVW growth benchmark the position is +1.35% over the forecast window.
Immix Biopharma's market cap is $590.06M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where IMMX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
8 daily calls for IMMX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Immix Biopharma in the 20th percentile on return on equity, where 100 is best.
Immix Biopharma is classified under Health Care / Biotechnology.
StockMap tracks Immix Biopharma as the 161st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Immix Biopharma ranks 187th of 394 in the group, against a group median of -0.27.